Matinas BioPharma | 8-K: Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
04:01
The Shanghai Stock Exchange will focus on facilitating the entry of medium and long-term funds into the market.
03:58
Optimizing fiscal "multiplication" to prioritize the issuance of larger-scale government Bonds.
03:55
More than 80% of companies have been surveyed, with the electronics and six other major industries receiving the most attention.
CSI SWS Health Care index+0.98%